Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 01, 2022

In Vivo T Cell–Depleted Reduced-Intensity Conditioned Allogeneic HSCT for Patients With ALL in First Remission

The Lancet Haematology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Haematology
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial
Lancet Haematol 2022 Apr 01;9(4)e276-e288, DI Marks, L Clifton-Hadley, M Copland, J Hussain, TF Menne, A McMillan, AV Moorman, N Morley, D Okasha, B Patel, P Patrick, MN Potter, CJ Rowntree, AA Kirkwood, AK Fielding

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading